Attention to the standardized combined therapy of adenocarcinoma of the esophagogastric junction        JI Jia-fu, JI Xin. Department of Gastrointestinal Tumor Surgery，Beijing Cancer Hospital, Peking University Cancer Hospital，Beijing 100142，China
Corresponding author: JI Jia-fu，E-mail:jiafuj@hotmail.com
Abstract    The incidence of adenocarcinoma of the esophagogastric junction (AEG) is dramatically increasing in Western countries, while it is not increasing in Eastern countries. Two surgical phase III trials have indicated that AEG type I should be treated surgically as esophageal cancer, and right thoracic approach with a mediastinal lymph node dissection may be recommended.While types II and III should be regarded as true gastric cancer, and a transhiatal extended gastrectomy is the preferable approach for type II and type III tumors. Meanwhile, perioperative chemotherapy and chemoradiotherapy have been approved in the clinical trials recently.